Compare · CI vs MSON
CI vs MSON
Side-by-side comparison of The Cigna Group (CI) and MISONIX, Inc. (MSON): market cap, price performance, sector, and recent activity on the wire.
Summary
- CI operates in Health Care, while MSON operates in Capital Goods - the two are in different parts of the market.
- CI is the larger of the two at $72.64B, about 157.1x MSON ($462.5M).
- CI has hit the wire 14 times in the past 4 weeks while MSON has been quiet.
- CI has more recent analyst coverage (25 ratings vs 2 for MSON).
- Company
- The Cigna Group
- MISONIX, Inc.
- Price
- $275.55-1.49%
- $26.23+3.72%
- Market cap
- $72.64B
- $462.5M
- 1M return
- +1.90%
- -
- 1Y return
- -17.71%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 1992
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 2
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
MISONIX, Inc.
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator, which is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system that provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.
Latest CI
- Director Foss Eric J was granted 782 shares, increasing direct ownership by 2% to 36,696 units (SEC Form 4)
- Director Mcclellan Mark B. was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Zarcone Donna F was granted 782 shares, increasing direct ownership by 3% to 27,517 units (SEC Form 4)
- Director Hathi Neesha was granted 782 shares, increasing direct ownership by 23% to 4,151 units (SEC Form 4)
- Director Mazzarella Kathleen M was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Kurian George was granted 782 shares, increasing direct ownership by 21% to 4,560 units (SEC Form 4)
- Director Ross Kimberly A. was granted 782 shares, increasing direct ownership by 17% to 5,294 units (SEC Form 4)
- Director Hennigan Michael J was granted 782 shares, increasing direct ownership by 138% to 1,350 units (SEC Form 4)
- Director Ozuah Philip was granted 782 shares, increasing direct ownership by 43% to 2,583 units (SEC Form 4)
- Director Wiseman Eric C was granted 782 shares, increasing direct ownership by 3% to 23,940 units (SEC Form 4)
Latest MSON
- SEC Form 4: Koby Michael returned 1,744,017 shares to the company
- SEC Form 4: Vizirgianakis Stavros G. returned 2,136,478 shares to the company, closing all direct ownership in the company
- SEC Form 4: Patton Thomas M returned 104,500 shares to the company, closing all direct ownership in the company
- SEC Form 4: Ludecker Robert S returned 319,443 shares to the company, closing all direct ownership in the company
- SEC Form 4: Laviolette Paul A returned 1,744,017 shares to the company
- SEC Form 4: Dwyer Joseph P returned 276,200 shares to the company, closing all direct ownership in the company
- SEC Form 4: Beyer Pat returned 20,000 shares to the company, closing all direct ownership in the company
- SEC Form RW filed by MISONIX, Inc.
- SEC Form 15-12B filed by MISONIX, Inc.
- MISONIX, Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits